AZ COMPUTATIONAL PATHOLOGY - Key Persons
Job Titles:
- VP and Head of Translational Science and Experimental Medicine, Respiratory and Immunology, AstraZeneca
As VP of Translational Science and Experimental Medicine (TSEM) for Respiratory and Immunology (R&I) at AstraZeneca, I am part of the R&I leadership team spanning the UK, Sweden and US. I designed and launched TSEM to provide a roadmap from novel targets to disease pathology and biomarkers, with precision medicine from the start, emphasising the importance of understanding the heterogeneity of common chronic disease.
Job Titles:
- Business Planning & Operations Director, Chief Operating Office, BioPharmaceuticals R & D
With a degree in biological sciences from the University of Cambridge, I joined AstraZeneca in February 2016 from global professional services firm, EY. I have previously worked for OC&C Strategy Consultants and rail construction company Crossrail.
As Business Planning & Operations Director, Chief Operating Office, BioPharmaceuticals R&D, I am working to ensure business operational excellence, drive efficient strategic decision making and support our scientific leadership. I am passionate about improving our business and making sure we can operate as effectively as possible to deliver the best outcomes for patients.
Job Titles:
- Chairman of InterPharmaLink AG
- Non - Executive Director / Member of the Board since August 2021
Committee membership: Member of the Sustainability Committee.
Skills and experience: Andreas joined the Board following the acquisition of Alexion, where he had been a Director since 2010. Previously he was at Novartis AG where he served on the Executive Committee from 2006 to 2010. He had been Group Head of Technical Operations and Quality from 2009 until 2010. He was Global CEO of Sandoz, the Generics Division of Novartis from 2004 to 2008, having originally joined in 1985. Andreas earned his PhD in pharmaceutical sciences from the University of Erlangen-Nuremberg and received his executive training in general management and leadership from IMD in Lausanne, INSEAD in Fontainebleau and Harvard Business School.
Other appointments: Andreas is Chairman of InterPharmaLink AG since 2011 and a director of various privately-held biotech and pharmaceutical companies
Job Titles:
- Senior Director, Global Media Relations
Job Titles:
- Non - Executive Director / Member of the Board since September 2023
Job Titles:
- Global Development Leader, Lokelma & Bydureon
I am the Global Development Leader for one of AstraZeneca's medicines in the renal and heart failure disease areas, so I have global responsibility for the late-stage development of the brand. That includes life-cycle studies and all the brand expansion work we do to support it.
Patients are at the heart of what we do. When you're in the pharmaceutical industry, you have the ability to help millions of patients with the right drug. So I believe, in our roles, that we are working for the many.
The people I work with, motivate me every day; it's all about trust and respect. Ultimately, the patients are at the heart of what we do. When you're a physician, you can help one patient at a time. In comparison, when you are in the pharmaceutical industry, you have the ability to help millions of patients with the right drug. So I believe, in our roles, that we are working for the many.
I have been involved in research and pharmaceutical development for more than 20 years, since being awarded a PhD in neurochemistry and neurotoxicology from Stockholm University, Sweden, in 1998. After spending time as a research fellow and as a preclinical scientist at Northwestern University medical school in Chicago, Illinois, I got the chance to join AstraZeneca in 2001, when the company opened a new laboratory in Sweden. I was drawn to the company because of its science-oriented focus and the opportunities this presented.
After being promoted to Therapy Area Clinical Director Cardiovascular, Renal and Metabolism in 2016, I relocated to Gaithersburg, where my role encompassed project work in renal strategy and tactics and supporting renal medicines under investigation to address chronic kidney disease and its complications.
Being part of the launch team on a new brand, as I am now, is very exciting. It's very interesting and extremely rewarding. I am very proud of my track record as a project leader, and the work I do to progress our products. Delivering a product is at the core of what we do, and without healthy product delivery we wouldn't be helping anybody.
My next target - a long-term goal of mine - is to become Global Medicines Leader.
Being part of the launch team is very exciting. It's very interesting and extremely rewarding. Delivering a product is at the core of what we do, and without healthy product delivery we wouldn't be helping anybody.
Job Titles:
- Chief Financial Officer
- Executive Director
- Executive Director and Chief Financial Officer / Member of the Board and CFO since August 2021
- Member of the Board and CFO
Skills and experience: Before joining AstraZeneca, Aradhana was CFO for Alexion, responsible for driving strategic growth, financial performance and business development. She has eight years of operational experience in biopharma, plus more than 20 years of professional experience at global financial institutions and extensive knowledge of global healthcare systems. This includes tenures at Citi Global Banking, UBS, and JP Morgan. Aradhana trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training at the University of Delhi and received her MBA from Stanford Business School.
Other appointments: Aradhana is on the Board of Governors of the American Red Cross and is an Independent Director and Audit Committee member of Anheuser-Busch InBev.
Job Titles:
- Vice President and Head of Translational Science & Experimental Medicine, Cardiovascular, Renal and Metabolism ( CVRM ), AstraZeneca
- VP and Head of Translational Science & Experimental Medicine, Cardiovascular, Renal and Metabolism, AstraZeneca
As Vice President and Head of Translational Science & Experimental Medicine for Cardiovascular, Renal and Metabolism (CVRM), I lead our human target validation, biomarker and precision medicine departments, working closely with team leaders in both early and late CVRM research. I help to direct our early-stage research priorities in CVRM and am involved in a multitude of initiatives across our early CVRM portfolio.
Our team's collective ambition is to stop, reverse, and one day, cure CRVM diseases by delivering innovative, life-changing medicines and solutions to patients. Across our departments, patients are always the starting point of our work. To that end, the foundation of our research relies heavily on human clinical data and biological samples, rather than cellular or animal modelling.
I completed my PhD and MD at the University of Cambridge, Departments of Clinical Biochemistry and Medicine and am currently a practicing endocrinologist. The time I spend with patients shapes my understanding of their needs as well as the gaps they experience in existing healthcare systems. This is both rewarding and incredibly valuable to the work I do each day at AstraZeneca.
Working across industry and applied medicine, a key priority for me as department head is ensuring we have a clear purpose as a team. I encourage open communication of priorities to foster a collaborative and stimulating work environment where we can work together to push the boundaries of science to deliver life-changing medicines to our patients.
Job Titles:
- Member of the Supervisory Board of ASML
- Non - Executive Director / Member of the Board since February 2025
Job Titles:
- Head, US External Communications
Job Titles:
- Senior Vice President and Global Head of R & I Late - Stage Development, BioPharmaceuticals R & D, AstraZeneca
- Senior Vice President and Global Head of Respiratory & Immunology Late - Stage Development, BioPharmaceuticals R & D, AstraZeneca
As Global Head of Respiratory & Immunology Late-Stage Development, I work with experts across biometrics, regulatory affairs, clinical operations, and clinical development. Together, we advance potential medicines from phase IIb through to submission and approval, and subsequently into life cycle management.
Despite important advances in recent years, there continues to be significant unmet need across respiratory and immunology diseases - from conditions like asthma and COPD affecting millions across the globe, to rare diseases with limited treatment options.
I joined AstraZeneca in 2022 and have been struck by the outstanding commitment to pushing the boundaries of science to transform care for people living with respiratory and immunology-based diseases. It is our ambition to move beyond symptom management towards disease modification and remission. Science thrives in an environment of true collaboration, so I am so pleased to see the innovative partnerships at play, both within AstraZeneca and externally, to help us realise this ambition.
I have a steadfast commitment to patients and clinical excellence, and I am so proud to lead a global network of people dedicated to developing new respiratory and immunology medicines. I have a passion for supporting my teams and people to grow.
Job Titles:
- Senior Director, Global Media Relations
Job Titles:
- Chief Scientist, Research and Early Development, Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals R & D, and Chair of AstraZeneca 's Postdoc Programme
- Chief Scientist, Research and Early Development, CVRM, BioPharmaceuticals R & D, and Chair of AstraZeneca 's Postdoc Programme
Chris is a renowned leader in the field of diabetes, obesity and metabolism research, with a career spanning over three decades. He has more than 180 published manuscripts, and has held industry and academic leadership roles at top institutions that include Harvard Medical School and the University of Washington. Chris is also Professor Emeritus at the University of Chicago, Department of Medicine.
Chris' research journey began in 1984 when he received his PhD in Biochemistry from the University of London. Soon after, he was quickly established as a pioneering force in the field of diabetes research-beginning with postdoctoral fellowships at the Joslin Diabetes Center/ Harvard Medical School and the University of Cambridge, then following with academic appointments and industry roles among some of the most venerated institutions in the US and the UK.
Chris' diabetes research has centered on the molecular mechanisms of insulin production and secretion, as well as signal transduction pathways that control pancreatic beta-cells growth and death in relation to the pathogenesis of diabetes. His work has earned him numerous awards and honors, as well as research funding from esteemed organisations such as the Juvenile Diabetes Research Foundation, American Diabetes Association and the National Institutes of Health. He also was a member of the National Institutes of Health Endocrinology and CADO Study Sections, an associate editor for Diabetes, the journal of the American Diabetes Association, a reviewer for multiple other peer-reviewed journals and is a frequent visiting professor and lecturer.
In 2015, Christopher joined AstraZeneca and in his role as Chief Scientist, is responsible for developing and growing the CVRM research base in the US and the UK, as well as contributing to the product development goals and vision across the CVRM therapeutic area. His research continues to focus on the molecular pathogenesis of both type 1 and type 2 diabetes, as well as the regulation of biosynthesis and production of polypeptide hormones; signal transduction mechanisms for insulin sensitivity; and novel pharmacological biologic targets for the treatment of metabolic diseases.
In May 2019, Chris's was announced as the new Chair of AstraZeneca's postdoctoral programme. His wealth of experience, strong links to academia and passion for biomedical education means he has the ideal background to continue to build this industry-leading programme.
Job Titles:
- Senior Vice President and Global Head of Pharmaceutical Technology and Development ( PT & D ), Global Operations
- SVP and Global Head of Pharmaceutical Technology and Development at Astrazeneca
Dafni is currently the SVP and Global Head of Pharmaceutical Technology and Development at Astrazeneca. She is leading a global network in eight countries and 16 locations of more than 1,200 innovative science and technology professionals who design, develop and commercialise new medicines and provide continuous improvement across the product life cycle.
With more than 25 years of experience in pharmaceutical development and technology at AstraZeneca and other large biopharmaceutical companies, she has repeatedly overseen product and process innovation and quality improvements that accelerated the development and delivery of medicines to patients faster and more efficiently.
Since joining AstraZeneca in 2016, Dafni has been instrumental in building a highly innovative technical organisation that has accelerated new medicine launches with robust processes into manufacturing, new drug synthesis and formulation platforms. She has pioneered a Chemistry, Manufacturing and Controls (CMC)-focused innovation group that delivers value through transforming drug delivery, process and analytical technologies, packaging and devices. Her organisation has also made significant contributions to sustainability with a number of projects advancing AstraZeneca's Ambition Zero Carbon.
Dafni is passionate about talent management and building high performing organisations. She has a deep appreciation for cultural diversity and drives equity and inclusion.
Dafni holds a Ph.D. in Materials Science and Engineering from the University of Pennsylvania, a Master of Science in Materials Science and Engineering from the University of Rochester, NY, and a Diploma in Chemical Engineering from the National Technical University of Athens.
My career roles have offered a unique vantage point bridging between R&D and manufacturing and creating value across the clinical and commercial supply chain. I have learned that influence comes from knowledge, courage and passion.
Job Titles:
- Executive Director and Head of Bioscience Metabolism, AstraZeneca
- Executive Director, Head of Bioscience Metabolism, Cardiovascular, Renal and Metabolism ( CVRM ), AstraZeneca
As Head of Bioscience Metabolism for Cardiovascular, Renal and Metabolism (CVRM), I am as a disease area leader seeking to understand the role of metabolism in disease and guiding our strategy for the early pipeline in Metabolism. This includes participating in the core strategy team and business development activities as well as being a champion for inclusion and diversity.
Job Titles:
- Executive Vice - President, Oncology Business Unit
Skills and experience: Dave was appointed Executive Vice-President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the commercial performance of the AstraZeneca global Oncology portfolio. He has global accountability for marketing, sales, medical affairs and market access in Oncology and plays a critical leadership role in setting the Oncology portfolio and product strategy. Previously, Dave served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions, including Oncology Business Unit Manager in Spain, and strategy, marketing and sales roles in the US. Prior to this, Dave worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. Dave is a graduate of Georgetown University in Washington DC.
Other appointments: Dave was appointed to the Board of Directors of Caris Life Sciences in August 2024.
Job Titles:
- Chairman of British International Investment Plc
- Non - Executive Director / Member of the Board since November 2020
Job Titles:
- Postdoctoral Researcher, Discovery Biology, Discovery Sciences, R & D
- Postdoctoral Researcher, Discovery Biology, Discovery Sciences, R & D, AstraZeneca
- Postdoctoral Researcher, Discovery Sciences, R & D, AstraZeneca
I am a Postdoctoral Researcher in the Discovery Sciences team, which develops new scientific methods for drug discovery. Discovery Sciences uses advanced screening methods of compounds to contribute to the early discovery of potential new drugs and supports other teams with delivering reagents, assays and disease models to discover new targets and medicines.
I completed my academic studies at the University of Helsinki, where I received my Ph.D. from the School of Pharmacy in 2017. As part of my education, I also spent one year as a visiting researcher at the University of Gothenburg.
During my academic career, I investigated the emerging field of extracellular vesicles, including `Exosomes´. Extracellular vesicles are nature's small transport vesicles that interact with many different cell types in the body mediating physiological and pathological functions. I researched the potential use of extracellular vesicles for the diagnosis and treatment of cancer. I discovered, among other things, how vesicles act as reservoirs for biomarkers, which can aid early diagnosis of cancer and help to identify which patients respond best to specific treatments. In 2017, my work was awarded the `Most Outstanding Doctoral Thesis´ in Pharmaceutical Sciences in Finland.
I started at AstraZeneca as a Postdoctoral Researcher in March 2017. Today, I work primarily with developing techniques for loading extracellular vesicles with therapeutic molecules and targeting them to disease tissues.
I am particularly interested in exploring the possibilities of using extracellular vesicles as biomarkers and in the delivery of therapeutics for future treatments. The use of extracellular vesicles can lead to faster, improved and more individualised diagnoses and treatments tailored to the specific needs of patients.
Job Titles:
- SVP, Late - Stage Development, Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals R & D
I am a scientific leader with more than 30 years' experience in treating patients with chronic conditions. The opportunity to innovate and push boundaries that can lead to life changing discoveries is what drives me every day. It's been a fantastic journey so far. I'm constantly being challenged and surprised, and I learn new things every day.
After training as an endocrinologist, I worked for 15 years in clinical practice and diabetes research at Uppsala University Hospital, in Sweden. I loved meeting so many different people and helping them live full lives in spite of their diabetes - and that still inspires my work today.
When I was asked in 2002 to come to work for AstraZeneca, it was the opportunity of a lifetime to develop groundbreaking medicines.
When I was asked in 2002 to come to work for AstraZeneca, it was the opportunity of a lifetime to develop groundbreaking medicines. My work shifted from treating patients individually to being able to help millions of people.
In my current role, I am in charge of development strategy and delivery across AstraZeneca's cardiovascular, renal and metabolism (CVRM) portfolio, which includes building up the entire franchises for each of these areas. I encourage my team to use new approaches to better understand the science behind the medicines. We are developing ways of treatment that are holistic - we are focused on treating the whole patient and addressing underlying risks.
Developing a greater understanding of what patients really need, and how our medicines can help them in this context, has been extremely rewarding. It has also enabled us to advance and bring together the CVRM franchises. I am really proud of the work my team is doing.
I am passionate about innovation and enjoy pushing boundaries to make breakthroughs that can change lives.
Job Titles:
- Senior Medical Lead, Late - Stage Development, Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals R & D
- Senior Medical Lead, Late - Stage Development, CVRM, BioPharmaceuticals R & D
I am a Senior Medical Lead in the focus area of Cardiovascular, Renal and Metabolism (CVRM) at AstraZeneca. In short, I work to get our new diabetes treatments approved worldwide. This involves, among other things, conducting clinical trials, presenting data for medical authorities and publishing trial results in various medical journals.
I started at AstraZeneca's R&D site in Lund at the end of 2009 as a Global Safety Physician. When the site in Lund was closed and certain operations were relocated to AstraZeneca in Gothenburg, I chose to also move to be able to continue my work.
I very much like my work, so we decided to move the whole family to Gothenburg. For me, it was an opportunity to extend my work in a field I am really passionate about; Cardiovascular, Renal and Metabolism (CVRM).
Within BioPharmaceuticals R&D, medicines are developed from idea to market approval. After three years in AstraZeneca´s Patient Safety department, I began working as a study physician, and later became Senior Medical Lead.
I am a double specialist in internal medicine and endocrinology, and came to AstraZeneca from Malmö University Hospital, where I conducted clinical work within internal medicine and endocrinology. I received my Ph.D. for preclinical diabetes research from Uppsala University, and I am an Associate Professor in endocrinology at Lund University. I also hold a degree in Pharmaceutical Medicine (ECPM) from the University of Basel.
Job Titles:
- Senior Director, Head of Cell Therapy Bioprocess Development and Manufacturing, BioPharmaceuticals R & D
I am the Senior Director and Head of Cell Therapy Bioprocess Development and Manufacturing, within the Cell Therapy Department of BioPharmaceuticals R&D at AstraZeneca. In this role, I am responsible for leading on the translational technology and development of high-quality cells for pre-clinical research, to enable the efficient research and development of cell-based therapeutics.
I bring more than 20 years of experience ranging from applied research through to manufacturing and regulatory compliance of stem cell-derived products. My expertise in stem cell biotechnology, standardisation and advanced therapies regulation areas has enabled my participation in several national and international committees where I have supported regulatory compliance and delivery of advanced therapy medicinal products.
I have a degree in Chemical Engineering and earned my Ph.D in Stem Cell Biotechnology from the Technical University of Lisbon. Since then, I have delivered on multiple collaborative projects, both in academia and within the UK Regulator (Medicines and Healthcare products Regulatory Agency), which assured the quality of clinical grade stem cell lines alongside a programme of cell and gene therapy standardisation.
The cell therapy department at AstraZeneca is a centralised hub of highly skilled people working together across disease areas to improve the lives of patients around the world. Each day I am excited to be a part of a team that maximises collaboration to show what science can do.
Job Titles:
- Lead / Head of Manufacturing for Coppell Supply Site, AstraZeneca
- PET Lead / Head of Manufacturing for Coppell Supply Site, AstraZeneca
Job Titles:
- Non - Executive Director / Member of the Board since October 2020
Committee membership: Chair of the Science Committee and member of the Nomination and Governance Committee.
Skills and experience: Euan studied physiology and medicine at Glasgow University, trained as a junior doctor at Oxford University Hospitals NHS Trust, and gained a DPhil in cardiovascular cellular biology and molecular genetics at the University of Oxford. In 2002, Euan moved to Stanford University, where his research focuses on genetic mechanisms of cardiovascular health and disease. His laboratory leverages AI and digital health tools, alongside biotechnology partners, to advance translational and clinical research. Euan's awards include recognition from the White House for contributions to personalised medicine and the American Heart Association's Medal of Honor for precision medicine.
Other appointments: Euan is the Arthur L. Bloomfield Professor of Medicine, Genetics and Biomedical Data Science, and the Chair of the Department of Medicine at Stanford University.
Job Titles:
- Director, Global Media Relations
Job Titles:
- Medical Lead Cell Therapies, BioPharmaceuticals R & D, AstraZeneca
I am the Medical Lead in BioPharmaceuticals R&D for Cell Therapies where I am responsible for guiding our strategies for cell therapy clinical applications. Our cross-functional team takes the biology to accelerate the delivery of new cell therapies to patients. A major part of my role is to collaborate closely with internal and external experts in the cell therapy field and related disciplines. Within AstraZeneca, this goes across all therapy areas, to leverage the existing and emerging platforms in stem cell technologies, new modalities, universal cell lines and CRISPR-mediated genome editing.
Job Titles:
- Transaction Director, Business Development Operations
I started my career within the start-up and biotech hub in Vancouver, Canada where I received my MBA as well. After a few years, I moved on to the Venture Capital (VC) environment in Sweden where I also had the opportunity to serve as the CEO of one of the VC firm's portfolio companies. During these first few years of my career, I gained broad experience in drug development and in running a small biotech. I also built up an extensive network of contacts within the Swedish and Canadian biotech communities.
I have more than 15 years of experience in the pharmaceutical industry. Most of this time I've spent honing my business development, partnering and transaction skills in both small and large pharma companies. In my current role as Transaction Director in Business Development Operations, I try to capitalise on the skills and experience gained in my previous roles. For example, as Head of Licensing at the privately-owned Swiss biotech, Debiopharm, I was responsible for all inbound and outbound transactions, as well as some of their commercial agreements. And as Associate Director in the Scientific Partnering and Alliances team at AstraZeneca, I provided transactional support to the early-stage Cardiovascular, Renal and Metabolism (CVRM) and Respiratory, Inflammation and Autoimmunity (RIA) teams. Before this, I was Head of Regulatory Product Strategy at Lundbeck, overseeing 14 marketed products in over 100 countries and working with a fantastic team.
When I first earned my pharmacist degree over 15 years ago, I could not even have dreamt that such a journey lay ahead of me. I have learnt so much since that time and I still feel just as curious as I did back then - and ready for more.
Outside of work, I spend most of my time with my family. My three-year-old daughter provides a lovely contrast to work, yet forces me to still use my negotiation skills. I also have a long history as a competitive triathlete; after 20 years in the sport, I have completed seven Ironman races. This has taught me skills that are also useful at work. For example, having a vision for what you want to achieve - and a realistic plan for getting there - helps maintain motivation when the going gets tough. Executing the plan requires discipline and focus and not leaving anything to chance. Yet it also forces you to focus on things you can influence rather than things outside your control - like the weather on race day. And even though you are alone during the race, you depend on a team to get there - my coach, my mechanic, my physiotherapist and my family have all been critical along the way.
Partnering is about bringing together the most talented people with different backgrounds to solve complex tasks, which I find very rewarding. In my role, I am fortunate to experience many different aspects of AstraZeneca's business and how it all fits together. The energy within these walls is remarkable.
Job Titles:
- Director, Media Relations, Sweden
Job Titles:
- Senior Data Scientist, Computer Vision, AstraZeneca
Job Titles:
- Director, Global Media Relations
Job Titles:
- Tower Lead for Global Supply Chain & Strategy and External Supply Manufacturing, Guadalajara GITC, AstraZeneca
Job Titles:
- Executive Vice - President, International
- Non - Executive Director of the Board of Directors of MyTomorrows
Skills and experience: Iskra was appointed as Executive Vice-President, International in December 2024. She is responsible for overall strategy and driving sustainable growth across the International region, which includes China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.
Prior to this role, Iskra held the role of EVP, Vaccines & Immune Therapies, where she was responsible for both the early and late-stage development of the Unit's pipeline and portfolio, including COVID-19 and RSV vaccines and monoclonal antibodies, strategic partnerships and acquisitions, medical affairs and commercial operations. Iskra has served on AstraZeneca's Senior Executive Team since 2017 when she was EVP for Europe & Canada. She has also held senior roles across Central & Eastern Europe, Middle East and Africa, and Eurasia.
Iskra has a PhD in Strategy and Leadership and an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia. She also holds a DMD from the Medical University of Zagreb.
Other appointments: Iskra was appointed as a non-executive director of the Board of Directors of myTomorrows in July 2024. She is also a member of the Steering Committee of the Partnership for Health System Sustainability and Resilience.
Jeff Pott - Chief Compliance Officer, Chief Legal Officer, CHRO
Job Titles:
- Chief Compliance Officer
- Chief Human Resources Officer
- General Counsel
Skills and experience: Jeff was appointed General Counsel in January 2009 and has overall responsibility for all aspects of AstraZeneca's Legal and IP function. In addition to his role as General Counsel, he was appointed Chief Human Resources Officer in January 2021 assuming additional responsibilities for the AstraZeneca Human Resources function and was appointed Chief Compliance Officer in January 2023. Jeff joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for IP, anti-trust and product liability litigation. Before joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and anti-trust advice and litigation. He received his Bachelor's degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law.
Job Titles:
- Chief Data Scientist, BioPharmaceuticals R & D, AstraZeneca
Job Titles:
- US Country President, BioPharmaceuticals Business Unit
Job Titles:
- Executive Director and Head of Bioscience COPD & IPF, Respiratory & Immunology ( R & I ), AstraZeneca
Job Titles:
- Executive Director and Head of Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism ( CVRM ), AstraZeneca
Job Titles:
- Head of Global Media Relations
Job Titles:
- Senior Director, International Communication
Job Titles:
- Head of Projects
- Vice - President, Head of Project Leaders, Early CVRM
Over the past two decades, I've discovered and developed novel medicines across all of AstraZeneca's major disease areas.
My first degree is in chemical engineering where I became interested in enzymes and molecular evolution. During my PhD I worked on methods to evolve protein variants with novel functionalities in the test tube. I then started my career in biotech before moving into R&D leadership and from there clinical development.
Job Titles:
- Principal Scientist, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R & D
Job Titles:
- Executive Director and Head of Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R & D
Job Titles:
- Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca
- Member of the Boards of JCR Pharmaceuticals
Skills and experience: Marc became CEO of Alexion, AstraZeneca's Rare Disease group, in August 2021 following its acquisition in July. He had previously served as an Executive Director and AstraZeneca's Chief Financial Officer from November 2013. Marc's career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.
Other appointments: Marc is a member of the Boards of JCR Pharmaceuticals and Cellectis.
Job Titles:
- Non - Executive Director / Member of the Board since April 1999
Committee membership: Member of the Science Committee and member of the Sustainability Committee
Skills and experience: Marcus has international business experience across various industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999.
Other appointments: Marcus is Chair of Skandinaviska Enskilda Banken AB, Saab AB, Wallenberg Investments AB and FAM AB. He is Vice-Chair of Investor AB and Vice-Chair of EQT AB. Marcus is also Chair of the Royal Swedish Academy of Engineering Sciences and a Board member of the Knut and Alice Wallenberg Foundation.
Job Titles:
- Senior Vice President and Head of Research and Early Development, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R & D
Job Titles:
- Vice President and Head of Microbial Sciences, BioPharmaceuticals R & D
Job Titles:
- Interim Senior Vice President Late - Stage Development, Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals R & D
Job Titles:
- Director, Global Media Relations
Job Titles:
- Non - Executive Chair of the Board / Member of the Board since September 2019 and Chair since April 2023
Committee membership: Chair of the Nomination and Governance Committee and member of the Remuneration Committee.
Skills and experience: Michel was previously Vice-Chairman of UBS Group AG (2010-2019), Chairman of Syngenta and Syngenta Foundation for Sustainable Agriculture (2013-2017) and Chairman of SwissHoldings (2013-2015). Between 2005 and 2013, Michel was CFO of ABB Ltd and interim CEO during 2008. He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005. Prior to that, he spent 18 years at The Dow Chemical Company, serving as CFO of Dow's Global Polyolefins and Elastomers division between 1997 and 2002.
Other appointments: Michel is a Non-Executive Director of Vodafone Group plc and Louis Dreyfus Int'l Holding BV and Chairman of IMD Business School.
Job Titles:
- Senior Vice President, Global Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals Business Unit
I hold the role of Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals Business Unit. In this role I address the unmet needs in four inter-related disease areas: metabolism, heart failure, cardiovascular disease and renal diseases, helping to drive our ambition to stop, reverse and cure these chronic, progressive and often time devastating diseases by maximising our medicines, delivering innovative solutions and advancing our pipeline.
I began my 30 year career in healthcare as a pharmacist and since then have helped to bring important medicines to people who have very few or limited options. I've joined the CVRM team with deep experience in marketing and sales, payer and access strategies, as well as leadership and engagement. Recognising the deep commitment we have in this important therapy area, I look forward to leading AstraZeneca into the future of CVRM care for the millions of people globally living with these conditions.
I joined our company more than two decades ago and have had increasing responsibility across the organisation and throughout multiple therapy areas. Most recently, I served as the SVP of US Respiratory & Immunology, delivering significant growth and expansion of the therapy area with several new product launches, including our first respiratory biologic, and the delivery of several innovative new approaches in digital health and patient centric support programs.
Job Titles:
- CEO of YewMaker
- Non - Executive Director / Member of the Board since June 2017
Committee membership: Chair of the Sustainability Committee, and member of the Nomination and Governance Committee, Remuneration Committee and Science Committee.
Skills and experience: Nazneen has significant experience in rare disease and cancer genomics and sustainable healthcare. She qualified in medicine from Oxford University, is an accredited specialist in medical genetics and has a PhD in molecular genetics. Nazneen was Professor of Genetics at the Institute of Cancer Research, Head of Cancer Genetics at the Royal Marsden NHS Foundation Trust, and founder and Director of the TGLclinical Genetic Testing Laboratory until 2018. In 2020, Nazneen founded YewMaker to build science-based sustainable healthcare solutions. Nazneen has a strong commitment to open science and has garnered numerous awards, including a CBE in recognition of her contribution to medical sciences.
Other appointments: Nazneen is CEO of YewMaker and Director of the Sustainable Medicines Partnership.
Job Titles:
- Director Physician, Nephrology Clinical Research
Job Titles:
- Executive Vice - President, Operations & Information Technology
- Executive Vice President, Global Operations, IT & Chief Sustainability Officer
- Non - Executive Director of the Smiths Group Plc Board
Skills and experience: Pam was appointed Executive Vice-President, Operations & Information Technology in June 2015 and assumed additional responsibility for the AstraZeneca Sustainability strategy and function in January 2023. Pam joined AstraZeneca after having spent 18 years with Merck/MSD in Global Manufacturing and Supply Chain and Commercial roles. Pam was the Head of Global Supply Chain Management & Logistics for Merck and led the transformation of Merck supply chains across the global supply network. Pam also held the role of President of MSD China, responsible for MSD's entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals. Pam holds Bachelor's and Master's degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York.
Other appointments: Pam serves as a Non-Executive Director of the Smiths Group plc Board and as a Trustee Member of the Board for Stevens Institute of Technology. Pam also serves as an Advisor to the International Society of Pharmaceutical Engineering (ISPE) Board of Directors.
Job Titles:
- Chief Executive Officer
- Executive Director
- Executive Director and Chief Executive Officer / Member of the Board and CEO since October 2012
- Member of the Board and CEO
Skills and experience: P: Pascal brings a passion for science and medicine, significant experience in established and emerging markets, strength of strategic thinking and execution, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as COO of Roche's pharmaceuticals division and, prior to that, as CEO of Genentech. Pascal has worked in senior management roles in several major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris. In 2022, Pascal received a knighthood for services to life sciences and leadership in the global response to the COVID-19 pandemic.
Other appointments: Pascal is on the Board of Sustainable Markets Initiative Limited.
Job Titles:
- Senior Vice President, Global Biologics Operations
Job Titles:
- Executive Director and Head of Bioscience Renal, Cardiovascular, Renal and Metabolism ( CVRM ), AstraZeneca
Job Titles:
- Head of Manufacturing for Coppell Supply Site, AstraZeneca
- PET Lead / Head of Manufacturing for Coppell Supply Site, AstraZeneca
As the Process Execution Team Lead and Head of Manufacturing for our Coppell Supply Site at AstraZeneca, I currently lead the manufacturing and technical teams responsible for the sole manufacture of a medicine that reaches millions of patients worldwide. I also drive strategy and operational excellence initiatives including safety, quality, lean manufacturing, while reinforcing our commitment to making the site a great place to work. I work across site teams to maximise our manufacturing resources and assets while building a platform to ensure long term growth and supply of our medicine in anticipation of current and future patient needs.
I have more than 15 years of experience in Process Engineering and Technology at AstraZeneca and other large biopharmaceutical and chemical manufacturing companies. During this time, I have gained experience in downstream manufacture of biologics medicine, organic and inorganic chemical manufacturing, aseptic manufacturing, validation, process development and design.
I am passionate about lean leadership, talent management, and building a highly motivated, high performing team and creating a fun and thriving work environment at AstraZeneca. I have a deep-seated belief that everyone should bring their whole self to work, so I work every day to foster a culturally diverse and inclusive work environment. I am a strong champion for bringing global inclusion and diversity programs to our site to build cultural awareness and intelligence.
Year-on-year reduction in operations deviation, driving high and consistent production schedule adherence, team leadership development and improved employee engagement.
Job Titles:
- Non - Executive Chair of Lancashire Holdings Limited
- Senior Independent Non - Executive Director / Member of the Board since April 2017 and Senior Independent Non - Executive Director since March 2021
Committee membership: Chair of the Audit Committee and member of the Remuneration Committee and Nomination and Governance Committee
Skills and experience: Philip was previously Group Finance Director of Prudential and Old Mutual. He has served as Chairman of the 100 Group of Finance Directors and as a member of the Takeover Panel. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Philip graduated in Philosophy, Politics and Economics from the University of Oxford, where he is a St Edmund Fellow, and holds an MSc in Behavioural Science from LSE.
Other appointments: Philip is the Non-Executive Chair of Lancashire Holdings Limited and serves as a Non-Executive Director of Legal & General Group plc.
Birgit Conix Non-Executive Director Member of the Board since February 2025 Committee Membership: Member of the Audit Committee Skills and experience: Birgit served Sonova as Chief Financial Officer and a Management Board member from 2021 to 2025. Previously, she was CFO and an Executive Board member at TUI from 2018 to 2021. Before TUI, she served as CFO of Telenet Group from 2013 to 2018. Prior to that, she held various senior positions at Johnson & Johnson, Heineken, Tenneco and Reed Elsevier. Birgit holds an MBA from the Booth School of Business, University of Chicago, and a Master of Science in Business Economics from the University of Tilburg. Other appointments: Birgit is a member of the Supervisory Board of ASML, where she is Chair of the ESG Committee and a member of the Audit Committee.
Skills and experience: DDeborah has more than 30 years' experience in healthcare and technology. She is currently President of Best Buy Health, which provides digital health solutions in ageing and care at home. Until the end of 2018, she served as General Manager of IBM Watson Health and prior to IBM, held multiple senior executive positions at Philips Healthcare where she also was Chief Executive Officer. Deborah has an appointment at and teaches Artificial Intelligence in Health at the Harvard TH Chan School of Public Health. She has been honoured by multiple organisations as a top health influencer. She holds an MBA from Babson College and is a Harvard University Advanced Leadership Initiative 2019 Fellow.
Job Titles:
- Senior Principal Scientist, Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R & D
Job Titles:
- Executive Director and Head of DMPK, Early CVRM, AstraZeneca
Job Titles:
- Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals R & D
Job Titles:
- Member of the Boards of Arm China
- Non - Executive Director / Member of the Board since January 2025
Skills and experience: Rene has been CEO of Arm and on the Arm Board since February 2022, and in September 2023, he led Arm's successful IPO. He has extensive experience in technology, computing, and AI, gained through various leadership roles in the semiconductor industry. Rene joined Arm in 2013 and before becoming CEO, he was President of Arm's IP Product Groups. Prior to Arm, Rene held roles at NVIDIA, Scintera Networks and Tensilica. Based in Silicon Valley, he spends significant time in the technology centres of the UK, Europe and Asia Pacific. Rene earned his Bachelor of Science in Electrical and Electronics Engineering from Clarkson University and is a graduate of the Stanford University Graduate School of Business Executive Education Program.
Other appointments: Rene is a member of the Boards of Arm China and SoftBank Group.
Anna Manz Non-Executive Director Member of the Board since September 2023 Committee Membership: Member of the Audit Committee. Skills and experience: Anna was CFO and a member of the Board of Directors of London Stock Exchange Group plc until 2024. From 2016 to 2020, she was an Executive Director and the CFO of Johnson Matthey Plc and, before that, spent 17 years at Diageo plc in a number of senior finance roles. She brings extensive expertise in accounting, corporate finance and M&A, as well as experience of business diversification, transformation and strategy. Anna was previously a Non-Executive Director of ITV plc and served on its Audit Committee and Remuneration Committee during most of that period. Other appointments: Anna is CFO of Nestlé S.A. and a member of Nestlé's Executive Board.
Skills and experience: Until February 2018, Sheri was CEO and a Director of Avon Products, Inc. and, prior to that, had a 30-year career at Johnson & Johnson (J&J), latterly serving as Vice-Chairman of the Executive Committee, responsible for the Pharmaceuticals and Consumer business segments. Sheri joined J&J as an R&D scientist and subsequently managed businesses in every major product sector. She holds a BSc in Textile Chemistry from the University of Massachusetts Dartmouth, an MSc in Chemical Engineering from Princeton University and an MBA from Rutgers University.
Job Titles:
- Director, Media Relations, Latin America
Job Titles:
- Executive Vice - President
- EVP and President, BioPharmaceuticals Business Unit
- Executive Vice - President, BioPharmaceuticals Business Unit
- Executive Vice - President, BioPharmaceuticals Business Unit, AstraZeneca
- Non - Executive Director of the Board of Almirall S.a
Skills and experience: Ruud was appointed Executive Vice-President, BioPharmaceuticals Business Unit in January 2019 and is responsible for product strategy and commercial delivery for CVRM, Respiratory and Immunology, and Vaccines & Immune Therapies. Prior to this, Ruud held the role of Executive Vice-President, North America and was responsible for driving growth and maximising the contribution of the commercial operations in North America. Ruud joined Astra (later to become AstraZeneca) in 1997 and has assumed leadership roles with increasing responsibility including Executive Vice-President, North America; Executive Vice-President, Europe; Regional Vice-President, Europe, Middle East and Africa; and Regional Vice-President, Asia Pacific. Ruud served as a member of the board and executive committee of the European Federation of Pharmaceutical Industries and Associations and was previously Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud holds a doctorate in immunology from the University of Leiden, Netherlands, beginning his career as a research scientist in immunology and ageing.
Other appointments: Ruud was appointed as a non-executive director of the Board of Almirall S.A. in June 2021.
Job Titles:
- Head of Bioscience Cell Therapy, BioPharmaceuticals R & D
Job Titles:
- Executive Vice - President
- Executive Vice - President, BioPharmaceuticals R & D
- Executive Vice - President, BioPharmaceuticals R & D, AstraZeneca
Skills and experience: Sharon was appointed as Executive Vice-President, BioPharmaceuticals R&D in August 2023. She is responsible for discovery through to late-stage development across CVRM and Respiratory & Immunology. Prior to this role, Sharon served as Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca Rare Disease having joined in 2013. With more than 18 years of industry experience she has previously led translational research, precision medicines, and global drug development teams. Sharon received her PhD in molecular biology from New York University, and completed a postdoctoral fellowship focused on mechanisms of DNA Damage and Repair at Stanford University. In 2022, Sharon was recognised as a Healthcare Businesswoman's Association Luminary in recognition of her transformational leadership and passion for mentoring those around her.
Job Titles:
- Head of Drug Delivery, BioPharmaceuticals Development, R & D
Job Titles:
- Non - Executive Director / Member of the Board since October 2017
Job Titles:
- Data & Analytics Enabling Units Engineering Lead
Job Titles:
- Head of Early Respiratory & Immunology Statistics, Executive Director Statistics, AstraZeneca
Job Titles:
- Vice President, Commercial Digital Health, AstraZeneca
Job Titles:
- Principal Environmental Scientist
Job Titles:
- Executive Vice - President
- Executive Vice - President, Oncology R & D
- Executive Vice - President, Oncology R & D, AstraZeneca
Susan Galbraith is the Executive Vice President of Oncology R&D at AstraZeneca, with global accountability for the Oncology portfolio from discovery through to late-stage development. Susan is transforming the productivity and scientific output from Oncology R&D, leading the charge for exploring the next wave of cancer treatment regimens, including therapies that directly target cancer cells, others that harness the power of the immune system, and novel combinations that may result in deeper, more durable responses. To date, Susan has been instrumental in bringing 12 cancer medicines to patients.
A Clinical Oncologist by background, Susan trained in medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she was awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research (ICR) in 2017, admitted to Fellowship of the Academy of Medical Sciences in 2018 and elected to the Academy of the American Association for Cancer Research (AACR) in 2024.
Susan is well known in the scientific community for her thought leadership and collaboration with clinicians, academic physicians, governments and the broader pharmaceutical industry. In addition to her role with AstraZeneca, Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021-2024 she served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research (EACR) Advisory Council.
Job Titles:
- Executive Director and Head of Bioscience Asthma and Skin Immunity, Respiratory and Immunology ( R & I ), AstraZeneca
Job Titles:
- Director, Global Media Relations
Job Titles:
- Director, Data Science, AstraZeneca
Job Titles:
- President, AstraZeneca UK
Job Titles:
- Director, Global Media Relations
Job Titles:
- Non - Executive Director / Member of the Board since January 2019
Committee membership: Member of the Science Committee
Skills and experience: Tony is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His work includes multiple aspects of lung cancer research, including biomarker and molecular targeted therapy in lung cancer. Tony is the Past President of the International Association for the Study of Lung Cancer and a past Board member of the American Society of Clinical Oncology. He has achieved numerous awards including the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, Giant of Cancer Care, and the Bronze Bauhinia Star.
Other appointments: Tony is Non-Executive Director of HUTCHMED (China) Limited, member of the Scientific Advisory Board of Prenetics Global Limited and serves on the Board of Insighta.
Job Titles:
- Vice President, Global Franchise Head, Infection
Job Titles:
- Executive Group Director, Metabolism, Early Clinical Development, Cardiovascular, Renal and Metabolism ( CVRM ), BioPharmaceuticals R & D, AstraZeneca